Platelet activating factor

Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.

Cross Reference

Introduction

To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Platelet activating factor?

Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Platelet activating factor

MeSH term MeSH ID Detail
Respiratory Distress Syndrome, Adult D012128 15 associated lipids
Epilepsy D004827 35 associated lipids
Seizures D012640 87 associated lipids
Nerve Degeneration D009410 53 associated lipids
Birth Weight D001724 23 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Hypertension D006973 115 associated lipids
Ischemic Attack, Transient D002546 42 associated lipids
Cerebrovascular Disorders D002561 25 associated lipids
Nasal Polyps D009298 26 associated lipids
Leukemia, Myeloid, Acute D015470 19 associated lipids
Ear Diseases D004427 7 associated lipids
Hypersensitivity, Immediate D006969 14 associated lipids
Respiratory Hypersensitivity D012130 18 associated lipids
Subarachnoid Hemorrhage D013345 17 associated lipids
Leukemia, Experimental D007942 42 associated lipids
Diabetic Angiopathies D003925 20 associated lipids
Agranulocytosis D000380 7 associated lipids
Shock D012769 11 associated lipids
Polycythemia Vera D011087 13 associated lipids
Hyperalgesia D006930 42 associated lipids
Spinal Cord Injuries D013119 34 associated lipids
Ventricular Fibrillation D014693 16 associated lipids
Fever D005334 35 associated lipids
Anaphylaxis D000707 35 associated lipids
Pneumococcal Infections D011008 7 associated lipids
Thrombocytopenia D013921 15 associated lipids
Bronchial Spasm D001986 18 associated lipids
Shock, Septic D012772 11 associated lipids
Immune Complex Diseases D007105 9 associated lipids
Conjunctivitis D003231 7 associated lipids
Coronary Artery Disease D003324 47 associated lipids
Encephalomyelitis, Autoimmune, Experimental D004681 26 associated lipids
Dermatitis, Atopic D003876 19 associated lipids
Rheumatic Diseases D012216 7 associated lipids
Death, Sudden D003645 12 associated lipids
Vitamin E Deficiency D014811 29 associated lipids
Cardiomegaly D006332 31 associated lipids
Leukemia, T-Cell D015458 23 associated lipids
Carbon Monoxide Poisoning D002249 9 associated lipids
Neutropenia D009503 15 associated lipids
Extravasation of Diagnostic and Therapeutic Materials D005119 3 associated lipids
Meningioma D008579 11 associated lipids
Multiple Trauma D009104 2 associated lipids
Cluster Headache D003027 4 associated lipids
Blood Platelet Disorders D001791 12 associated lipids
Glomerulonephritis, IGA D005922 7 associated lipids
Behcet Syndrome D001528 7 associated lipids
Escherichia coli Infections D004927 17 associated lipids
Migraine Disorders D008881 11 associated lipids
Malabsorption Syndromes D008286 16 associated lipids
Pregnancy Complications, Cardiovascular D011249 11 associated lipids
Thrombasthenia D013915 4 associated lipids
Gastrointestinal Hemorrhage D006471 27 associated lipids
Disseminated Intravascular Coagulation D004211 7 associated lipids
Shock, Traumatic D012774 4 associated lipids
Hemorrhagic Fever, American D006478 2 associated lipids
Fetal Growth Retardation D005317 9 associated lipids
Bronchial Hyperreactivity D016535 15 associated lipids
Arthus Reaction D001183 8 associated lipids
Thrombocytosis D013922 4 associated lipids
Toxemia D014115 3 associated lipids
Vitamin D Deficiency D014808 13 associated lipids
Duodenal Ulcer D004381 12 associated lipids
Angina Pectoris D000787 27 associated lipids
Angina, Unstable D000789 14 associated lipids
Pregnancy Complications, Hematologic D011250 11 associated lipids
Heart Defects, Congenital D006330 20 associated lipids
Klebsiella Infections D007710 7 associated lipids
Ascites D001201 25 associated lipids
Albuminuria D000419 18 associated lipids
Infant, Premature, Diseases D007235 7 associated lipids
Hyperinsulinism D006946 27 associated lipids
Scleroderma, Systemic D012595 16 associated lipids
Parkinson Disease D010300 53 associated lipids
Rhinitis, Allergic, Seasonal D006255 7 associated lipids
Salmonella Infections, Animal D012481 9 associated lipids
Bronchial Diseases D001982 3 associated lipids
Central Nervous System Diseases D002493 10 associated lipids
Tangier Disease D013631 8 associated lipids
Heart Arrest D006323 13 associated lipids
Cystitis D003556 23 associated lipids
Cholecystitis D002764 8 associated lipids
HIV Infections D015658 20 associated lipids
Subacute Sclerosing Panencephalitis D013344 3 associated lipids
Dermatitis, Allergic Contact D017449 20 associated lipids
AIDS Dementia Complex D015526 4 associated lipids
Constriction, Pathologic D003251 8 associated lipids
Medulloblastoma D008527 22 associated lipids
Zellweger Syndrome D015211 39 associated lipids
Coronary Thrombosis D003328 7 associated lipids
Glomerulonephritis, Membranous D015433 6 associated lipids
Peripheral Vascular Diseases D016491 8 associated lipids
Bronchopulmonary Dysplasia D001997 4 associated lipids
Hypertension, Portal D006975 12 associated lipids
Atherosclerosis D050197 85 associated lipids
Leukemia-Lymphoma, Adult T-Cell D015459 25 associated lipids
Metabolic Syndrome D024821 44 associated lipids
Dyslexia D004410 3 associated lipids
Leukemia, Eosinophilic, Acute D015472 3 associated lipids
Per page 10 20 50 100 | Total 288

PubChem Associated disorders and diseases

What pathways are associated with Platelet activating factor

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Platelet activating factor?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Platelet activating factor?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Platelet activating factor?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Platelet activating factor?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Platelet activating factor?

Knock-out

Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).

Mouse Model

Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).

Transgenic Model

Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Platelet activating factor

Download all related citations
Per page 10 20 50 100 | Total 8526
Authors Title Published Journal PubMed Link
Satouchi K et al. Application of selected ion monitoring to determination of platelet-activating factor. 1983 J. Biochem. pmid:6423622
Hillmar I and Zöllner N Saturated and unsaturated 1-0-alkyl-2-0-acetoyl-sn-glycero-3-phosphocholines and 2-lyso derivatives from ratfish liver oil. Effect on adenosine 3':5'-cyclic monophosphate concentration in hepatocyte suspensions. 1983 Res Exp Med (Berl) pmid:6310713
Mauco G et al. Platelet activating factor (PAF-acether) promotes an early degradation of phosphatidylinositol-4,5-biphosphate in rabbit platelets. 1983 FEBS Lett. pmid:6311620
Wasserman SI Mediators of immediate hypersensitivity. 1983 J. Allergy Clin. Immunol. pmid:6193157
Drapier JC et al. Lipid-mediator synthesis in peritoneal macrophages from mice injected with immunostimulants. 1983 Biochim. Biophys. Acta pmid:6131693
Otsuka A et al. alpha-Adrenergic blocking action of 1-O-hexadecyl-2-O-acetyl-sn-glycero-3-phosphocholine in rats. 1983 Clin Exp Hypertens A pmid:6133661
Jouvin-Marche E et al. Effect of the Ca2+ antagonist nifedipine on the release of platelet-activating factor (PAF-acether), slow-reacting substance and beta-glucuronidase from human neutrophils. 1983 Eur. J. Pharmacol. pmid:6134631
Hopkins NK et al. Evidence for mediation of acetyl glyceryl ether phosphorylcholine stimulation of adenosine 3',5'-(cyclic)monophosphate levels in human polymorphonuclear leukocytes by leukotriene B4. 1983 Biochim. Biophys. Acta pmid:6313071
Haddad ZH and Green A State--and dynamics--of the art: a current review. IgE-mediated immediate hypersensitivity reactions: cellular events and pharmacologic mediators. 1983 J Asthma pmid:6190793
Mencia-Huerta JM et al. Antigen-initiated release of platelet-activating factor (PAF-acether) from mouse bone marrow-derived mast cells sensitized with monoclonal IgE. 1983 J. Immunol. pmid:6315819
Czarnetzki B Increased monocyte chemotaxis towards leukotriene B4 and platelet activating factor in patients with inflammatory dermatoses. 1983 Clin. Exp. Immunol. pmid:6317241
Stimler NP and O'Flaherty JT Spasmogenic properties of platelet-activating factor: evidence for a direct mechanism in the contractile response of pulmonary tissues. 1983 Am. J. Pathol. pmid:6624879
Sano K et al. A role of calcium-activated phospholipid-dependent protein kinase in human platelet activation. Comparison of thrombin and collagen actions. 1983 J. Biol. Chem. pmid:6218169
Vargaftig BB et al. Synergized activation of human platelets by epinephrine and platelet-activating factor-acether is adenosine diphosphate and thromboxane A2-independent. 1983 Adv. Prostaglandin Thromboxane Leukot. Res. pmid:6221558
Voelkel NF et al. Platelet-activating factor causes pulmonary vasoconstriction and edema via platelet-independent leukotriene formation. 1983 Adv. Prostaglandin Thromboxane Leukot. Res. pmid:6221590
Kloprogge E et al. Properties of PAF-acether-induced platelet aggregation and secretion. Studies in gel-filtered human platelets. 1983 Thromb. Res. pmid:6222507
Hartung HP Acetyl glyceryl ether phosphorylcholine (platelet-activating factor) mediates heightened metabolic activity in macrophages. Studies on PGE, TXB2 and O2- production, spreading, and the influence of calmodulin-inhibitor W-7. 1983 FEBS Lett. pmid:6309563
Swendsen CL et al. 1-O-alkyl-2-acyl-sn-glycero-3-phosphocholine: a novel source of arachidonic acid in neutrophils stimulated by the calcium ionophore A23187. 1983 Biochem. Biophys. Res. Commun. pmid:6407484
Shukla SD et al. Acetylglyceryl ether phosphorylcholine. A potent activator of hepatic phosphoinositide metabolism and glycogenolysis. 1983 J. Biol. Chem. pmid:6309795
Hallam TJ et al. The role of 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine (AcGEPC) and palmitoyl-lysophosphatidate in the responses of human blood platelets to collagen and thrombin. 1983 FEBS Lett. pmid:6617886
Roussi J et al. [Success of treatment with a low-molecular-weight heparin fraction in a case of pulmonary embolism complicated by heparin-induced thrombopenia]. 1983 Nouv Rev Fr Hematol pmid:6622253
Randolph AE et al. Blood pressure and heart rate effects of alkyl ether phospholipids in conscious renal, spontaneously hypertensive, and normotensive rats. 1983 Clin Exp Hypertens A pmid:6684006
Morley J et al. Inflammatory actions of platelet activating factor (Pafacether) in guinea-pig skin. 1983 Br. J. Pharmacol. pmid:6685552
Hornby EJ and Perry CR 1-O-hexadecyl-2-acetyl-sn-3-glycerophosphorylcholine (PAF): some effects on the aggregation of human platelets by thrombin or collagen. 1983 Thromb. Haemost. pmid:6636035
Patterson R and Harris KE The activity of aerosolized and intracutaneous synthetic platelet activating factor (AGEPC) in rhesus monkeys with IgE-mediated airway responses and normal monkeys. 1983 J. Lab. Clin. Med. pmid:6644157
Nunn B Total and selective desensitisation of human platelets to synthetic platelet activating factor (PAF): evidence that extracellular PAF does not mediate collagen-induced aggregation. 1983 Thromb. Res. pmid:6648898
Myers A et al. Glucocorticoid protection against PAF-acether toxicity in mice. 1983 Br. J. Pharmacol. pmid:6652344
Cervoni P et al. Aortic vascular and atrial responses to (+/-)-1-O-octadecyl-2-acetyl-glyceryl-3-phosphorylcholine. 1983 Br. J. Pharmacol. pmid:6652348
Ogihara T et al. [Renomedullary hypotensive lipids and prostaglandins]. 1983 Horumon To Rinsho pmid:6368051
Benveniste J et al. The actions of Paf-acether (platelet-activating factor) on guinea-pig isolated heart preparations. 1983 Br. J. Pharmacol. pmid:6652376
Garcia Gil M and Sanchez Crespo M Dansylcadaverine and rimantadine inhibition of phagocytosis, PAF-acether release, and phosphatidylcholine synthesis in human polymorphonuclear leukocytes. 1983 Immunopharmacology pmid:6654649
Holt PG et al. Platelet serotonin release by human polymorphonuclear leucocytes stimulated by cotton dust bacteria. 1983 Clin. Exp. Immunol. pmid:6831770
McDonald TP and Kalmaz GD Effects of thrombopoietin on the number and diameter of marrow megakaryocytes of mice. 1983 Exp. Hematol. pmid:6832243
Lewis JC et al. Platelet-activating factor effects on pulmonary ultrastructure in rabbits. 1983 Exp. Mol. Pathol. pmid:6832335
Billah MM and Johnston JM Identification of phospholipid platelet-activating factor (1-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine) in human amniotic fluid and urine. 1983 Biochem. Biophys. Res. Commun. pmid:6407483
Chilton FH et al. Selective acylation of lyso platelet activating factor by arachidonate in human neutrophils. 1983 J. Biol. Chem. pmid:6408071
Hartung HP et al. Platelet activating factor (PAF) induces the oxidative burst in macrophages. 1983 Int. J. Immunopharmacol. pmid:6874164
1st International Symposium on Platelet-Activating Factor (PAF-ACETHER, AGEPC) and structurally related ether-lipids. Paris (France) June 26-29, 1983. Abstracts. 1983 J Pharmacol pmid:6876807
Cargill DI et al. Aggregation, release and desensitization induced in platelets from five species by platelet activating factor (PAF). 1983 Thromb. Haemost. pmid:6879508
Suquet CM and Leid RW Aggregation of equine platelets by PAF (platelet-activating factor). 1983 Inflammation pmid:6862593
Virella G et al. Release of PAF by human polymorphonuclear leucocytes stimulated by immune complexes bound to Sepharose particles and human erythrocytes. 1983 Immunology pmid:6885111
Blank ML and Snyder F Improved high-performance liquid chromatographic method for isolation of platelet-activating factor from other phospholipids. 1983 J. Chromatogr. pmid:6863454
Camussi G et al. Platelet-activating factor-mediated contraction of rabbit lung strips: pharmacologic modulation. 1983 Immunopharmacology pmid:6885382
Simrock R et al. [Reversible inhibition of thrombocyte stimulation by acetylsalicylic acid and its role in antithrombotic therapy]. 1983 Klin. Wochenschr. pmid:6865264
Hadváry P and Baumgartner HR Activation of human and rabbit blood platelets by synthetic structural analogs of platelet activating factor. 1983 Thromb. Res. pmid:6868019
O'Flaherty JT and Wykle RL Biology and biochemistry of platelet-activating factor. 1983 Clin Rev Allergy pmid:6370406
Tiffany ML Technical considerations for platelet aggregation and related problems. 1983 Crit Rev Clin Lab Sci pmid:6370596
Vermylen J et al. Normal mechanisms of platelet function. 1983 Clin Haematol pmid:6301715
Pieroni G and Hanahan DJ Metabolic behavior of acetyl glyceryl ether phosphorylcholine on interaction with rabbit platelets. 1983 Arch. Biochem. Biophys. pmid:6870274
Iñarrea P et al. Platelet-activating factor: an effector substance of the vasopermeability changes induced by the infusion of immune aggregates in the mouse. 1983 Immunopharmacology pmid:6347969
Satouchi K [Platelet activating factor (PAF)--a new chemical mediator of inflammation]. 1983 Seikagaku pmid:6350499
McGowan EB and Detwiler TC Characterization of the thrombin-induced desensitization of platelet activation by thrombin. 1983 Thromb. Res. pmid:6356458
Weksler BB Platelets and the inflammatory response. 1983 Clin. Lab. Med. pmid:6360503
Machin SJ et al. Defective platelet aggregation to the calcium ionophore A23187 in a patient with a lifelong bleeding disorder. 1983 J. Clin. Pathol. pmid:6413552
Alam I et al. Metabolism of platelet-activating factor by blood platelets and plasma. 1983 Lipids pmid:6413803
Pinckard RN Platelet-activating factor. 1983 Hosp. Pract. (Off. Ed.) pmid:6414941
Camussi G et al. The release of platelet-activating factor from human endothelial cells in culture. 1983 J. Immunol. pmid:6415166
Bonnet J et al. Dependency of the Paf-acether induced bronchospasm on the lipoxygenase pathway in the guinea-pig. 1983 Prostaglandins pmid:6419289
Lin AH et al. Acetyl glyceryl ether phosphorylcholine stimulates leukotriene B4 synthesis in human polymorphonuclear leukocytes. 1982 J. Clin. Invest. pmid:6290535
Vargaftig BB et al. Adrenaline and PAF-acether synergize to trigger cyclooxygenase-independent activation of plasma-free human platelets. 1982 Thromb. Res. pmid:7164036
Page CP et al. An in vivo model for studying platelet aggregation and disaggregation. 1982 Thromb. Haemost. pmid:7051409
Mencia-Huerta JM et al. Biosynthesis of platelet-activating factor (PAF)acether). III. Formation of PAF-acether from synthetic substrates by stimulated murine macrophages. 1982 J. Immunol. pmid:7086143
Namm DH et al. Species specificity of the platelet responses to 1-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine. 1982 Thromb. Res. pmid:7071810
Keraly CL and Benveniste J Specific desensitization of rabbit platelets by platelet-activating factor (PAF-acether) and derivatives. 1982 Br. J. Haematol. pmid:7082588
Wykle RL et al. Platelet activating factor (1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine). Activity of analogs lacking oxygen at the 2-position. 1982 FEBS Lett. pmid:7084476
Sánchez-Crespo M et al. Vascular actions of synthetic PAF-acether (a synthetic platelet-activating factor) in the rat: evidence for a platelet independent mechanism. 1982 Immunopharmacology pmid:7085259
Bach MK Mediators of anaphylaxis and inflammation. 1982 Annu. Rev. Microbiol. pmid:6128957
Mueller HW et al. Ether lipid content and fatty acid distribution in rabbit polymorphonuclear neutrophil phospholipids. 1982 Lipids pmid:7087685
Haslam RJ and Vanderwel M Inhibition of platelet adenylate cyclase by 1-O-alkyl-2-O-acetyl-sn-glyceryl-3-phosphorylcholine (platelet-activating factor). 1982 J. Biol. Chem. pmid:6177688
Page CP et al. Platelet activation in asthma. 1982 N. Engl. J. Med. pmid:7088080
Chilton FH et al. Platelet activating factor. Stimulation of the lipoxygenase pathway in polymorphonuclear leukocytes by 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine. 1982 J. Biol. Chem. pmid:6802816
Vargaftig BB et al. Degranulation of rabbit platelets with PAF-acether: a new procedure for unravelling the mode of action of platelet-activating substances. 1982 Thromb. Haemost. pmid:7135345
Sancho J et al. The effect of the injection of a synthetic platelet-activating factor (PAF-acether) on the fate of IgG aggregates in mice. 1982 Immunology pmid:7141463
Sybertz EJ et al. Studies on the interactions of acetyl glycerol ether phosphoryl choline with the sympathetic nervous system in rats. 1982 J. Pharmacol. Exp. Ther. pmid:7143227
Cabot MC et al. Metabolism of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine by cell cultures. 1982 Life Sci. pmid:7162357
Tsien WH et al. Variable responses of human platelets to synthetic platelet activating factor and their modification by epinephrine. 1982 Thromb. Res. pmid:7164038
Vargaftig BB Platelet-activating factor (PAF-acether) 1982 Agents Actions pmid:7164939
Bette P and Bienvenue A Exchange of a spin-labeled analog of PAF-acether between micelles, serum albumin and model membranes. 1982 Agents Actions pmid:7164940
Lartigue-Mattei C et al. Pharmacokinetic study of PAF-acether. Preliminary results after the intravenous administration of a 3H-labelled product to the rabbit. 1982 Agents Actions pmid:7164941
Morgat JL et al. Radio-labelling of 1-O-alkyl, 2-O-acetyl, sn-glycero-3-phosphorylcholine, 1-O-(9,10-di3H)-octadecyl PAF-acether. 1982 Agents Actions pmid:7164942
Convert O et al. 1H NMR of PAF-acether: influence of solvent on its structure. 1982 Agents Actions pmid:7164943
Borrel MC et al. Additional techniques for the total synthesis of PAF-acether. 1982 Agents Actions pmid:7164944
Chignard M et al. Inhibition by sulphinpyrazone of the platelet-dependent bronchoconstriction due to platelet-activating factor (PAF-acether) in the guinea pig. 1982 Eur. J. Pharmacol. pmid:6804248
Shukla SD and Hanahan DJ AGEPC (platelet activating factor) induced stimulation of rabbit platelets: effects on phosphatidylinositol, di- and triphosphoinositides and phosphatidic acid metabolism. 1982 Biochem. Biophys. Res. Commun. pmid:6288030
Lüscher EF The role of blood cells and of the vessel wall in the induction of intravascular coagulation. 1982 Klin. Wochenschr. pmid:6750223
Czarneztki BM Effect of platelet activating factor on leukocytes. II. Enhancement of eosinophil chemotactic factor and beta-glucuronidase release. 1982 Chem. Phys. Lipids pmid:6814773
Basran GS et al. Cromoglycate (DSCG) inhibits responses to platelet-activating factor (PAF-acether) in man: an alternative mode of action for DSCG in asthma? 1982 Eur. J. Pharmacol. pmid:6819153
Shaw JO and Lyons RM Requirements for different Ca2+ pools in the activation of rabbit platelets. I. release reaction and protein phosphorylation. 1982 Biochim. Biophys. Acta pmid:6800409
Aderka D et al. Morphological platelet anomalies in thrombotic thrombocytopenic purpura. 1982 Acta Haematol. pmid:6801893
Benveniste J et al. Biosynthesis of platelet-activating factor (PAF-ACETHER). II. Involvement of phospholipase A2 in the formation of PAF-ACETHER and lyso-PAF-ACETHER from rabbit platelets. 1982 Thromb. Res. pmid:6803388
Roubin R et al. Biosynthesis of platelet-activating factor (PAF-acether). IV. Impairment of acetyl-transferase activity in thioglycollate-elicited mouse macrophages. 1982 J. Immunol. pmid:6806384
Lee TC et al. Activities of enzymes that metabolize platelet-activating factor (1-Alkyl-2-acetyl-sn-glycero-3-phosphocholine) in neutrophils and eosinophils from humans and the effect of a calcium ionophore. 1982 Biochem. Biophys. Res. Commun. pmid:6808993
Yasaka T et al. Monocyte aggregation and superoxide anion release in response to formyl-methionyl-leucyl-phenylalanine (FMLP) and platelet-activating factor (PAF). 1982 J. Immunol. pmid:6278021
Morgan WK et al. Byssinosis: some unanswered questions. 1982 Am. Rev. Respir. Dis. pmid:6808880
Miller OV et al. Acetyl glycerylphosphorylcholine inhibition of prostaglandin I2-stimulated adenosine 3',5'-cyclic monophosphate levels in human platelets. Evidence for thromboxane A2 dependence. 1982 Biochim. Biophys. Acta pmid:6285985
Lapetina EG Platelet-activating factor stimulates the phosphatidylinositol cycle. Appearance of phosphatidic acid is associated with the release of serotonin in horse platelets. 1982 J. Biol. Chem. pmid:7045103
Hartung HP et al. Stimulation of the oxidative burst in macrophages with platelet activating factor (PAF-acether). 1982 Agents Actions Suppl. pmid:6960648
Camussi G et al. Release of platelet-activating factor from HL-60 human leukemic cells following macrophage-like differentiation. 1982 Blood pmid:6947829
Ishii H et al. A platelet aggregating substance contained in xanthine oxidase preparation from cow's milk. 1982 Thromb. Res. pmid:6897588
Smith RJ and Bowman BJ Stimulation of human neutrophil degranulation with 1-O-octadecyl-2-O-acetyl-SN-glyceryl-3-phosphorylcholine: modulation by inhibitors of arachidonic acid metabolism. 1982 Biochem. Biophys. Res. Commun. pmid:6803804